ZIA BC 011353 (ZIA) | |||
---|---|---|---|
Title | Validation of, and therapeutic evaluation in ovarian cancer GEM models | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Van Dyke, Terry | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $172,904 | Project Dates | 01/01/2009 - 00/00/0000 |
Fiscal Year | 2015 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Chemoprevention (15.0%) Chemotherapy (25.0%) Metastasis (20.0%) |
Ovarian Cancer (100.0%) | ||
Research Type | |||
Development and Characterization of Model Systems Application of Model Systems |
|||
Abstract | |||
We verified that the SEOC GDA models respond to cisplatin or olaparib similarly to patients. olaparib is efficacious only for BRCA deficient tumors and cisplatin is optimally effective in these tumors. The combination of these two drugs for BRCA deficient tumors is no more efficacious than cisplatin alone. We have evaluated consolidated therapy for BRCA1-deficient GDA tumors in which mice are treated with cisplatin to debulk tumors followed by treatment with an FDA-approved drug shown in drug library screens to be effective at killing both human and mouse SEOC derived cells in 2-D culture. With standard routes of introduction, the compound was not more effective than the vehicle control. We are now evaluating the efficacy of this drug when delivered by implanted continuous dosing pumps. Studies for all other objectives are currently in progress. |